| Study, Year | Group | N | Mean Procedure Time in Minutes (SD) | Stenting n/N (%) | Direct Stenting n/N (%) | Procedural GP2B3Ai Use n/N (%) | Anti-platelet Drugs Used | Anti-thrombotic Drugs Used |
|---|---|---|---|---|---|---|---|---|
| Duan, 2010 | PercuSurge Guardwire Plus | 46 | --- | 46/46 (100) | --- | --- | Aspirin 300mg and clopidogrel 300mg followed by 75mg pre-PCI | UFH 70U/kg to achieve an ACT of 300s |
| Control | 50 | --- | 50/50 (100) | --- | --- | |||
| Pan, 2010 | PercuSurge Guardwire | 52 | --- | --- | --- | 52/52 (100) | Aspirin 300mg and clopidogrel 300mg pre-PCI | --- |
| Control | 52 | --- | --- | --- | 52/52 (100) | --- | ||
| Tahk, 2008 | PercuSurge GuardWire | 60 | --- | 60/60 (100) | 0/60 (0) | --- | Aspirin 300 mg and clopidogrel 300-600 mg pre-PCI | Heparin IV during PCI (ACT 300 s) |
| Control | 56 | --- | 56/56 (100) | 1/56 (1.8) | --- | |||
| Hahn, 2007 | GuardWire | 19 | --- | 19/19 (100) | --- | 1/19 (5.3) | Appropriate antiplatelet therapy | Heparin |
| Control | 20 | --- | 29/20 (100) | --- | 1/20 (5.0) | |||
| Matsuo, 2007 | GuardWire Distal Protection System | 80 | 75.8 (30) | --- | --- | 9/80 (11) | Aspirin 100 mg and ticlopidine 200 mg pre-PCI | Heaparin 5000 U (ACT >250 s) |
| Control | 74 | 53 (25) | --- | --- | 5/74 (7) | |||
| Muramatsu, 2007 | GuardWire Plus System | 173 | 29.7 (18.3)* | 173/173 (100) | --- | --- | Aspirin 81-100 mg/d and ticlopidine 200 mg/d for at least 2 weeks | --- |
| Control | 168 | 29.5 (18.2)* | 168/168 (100) | --- | --- | --- | ||
| Zhou, 2007 | PercuSurge GuardWire | 52 | --- | 52/52 (100) | --- | 0/52 (0) | Aspirin 300 mg and clopidogrel 300 mg pre-PCI then aspirin 100 mg/d and clopidogrel 75 mg/d post-PCI | Heparin IV during PCI (ACT ≥300 s) |
| Control | 60 | --- | 60/60 (100) | --- | 0/60 (0) | |||
| Okamura, 2005 | PercuSurge GuardWire | 8 | --- | 8/8 (100) | --- | --- | Aspirin 243 mg at least 30 min pre-PCI | Heparin 100 U/kg IV |
| Control | 8 | --- | 8/8 (100) | --- | --- | |||
| Stone, 2005 | GuardWire Plus | 252 | 53 (42-69)† | 244/252 (96.8) | --- | 210/252 (83.3) | Aspirin 324 mg and clopidogrel 300 mg pre-PCI | Heparin IV 70 U/kg bolus (ACT >300 s pre-PCI or 200-300 s if GP2B3Ai used) |
| Control | 249 | 39 (29-51)† | 241/249 (96.8) | --- | 208/249 (83.5) | |||
Operation time;
Median (interquartile range)
Abbreviations: ACT=activated clotting time; d=days; GP2B3Ai=glycoprotein IIbIIIa inhibitor; IV=intravenous; kg=kilogram; mg=milligram; min=minutes; n=number; N=number of participants in the group; PCI=percutaneous coronary intervention; s=seconds; SD=standard deviation; U=units
From: Appendix E, Baseline and Procedural Characteristics of Included Trials and Studies
NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.